Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN0361 in hypertriglyceridemia
NCT06471543Phase 2Active, not recruiting
- Sponsor
- Ikaria
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing RN0361 with Placebo (2 arms). Primary endpoints: Adverse Events/Serious Adverse Events at 85 days, Apolipoprotein C3 Change from Baseline at 183 days and 1 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
RN0361
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT06471543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471543.